Novavax Files 8-K Report

Ticker: NVAX · Form: 8-K · Filed: Jun 6, 2024 · CIK: 1000694

Novavax Inc 8-K Filing Summary
FieldDetail
CompanyNovavax Inc (NVAX)
Form Type8-K
Filed DateJun 6, 2024
Risk Levellow
Pages5
Reading Time6 min
Key Dollar Amounts$0.01
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, regulation-fd, financials

Related Tickers: NVAX

TL;DR

NOVAVAX filed an 8-K, check for updates.

AI Summary

On June 6, 2024, Novavax, Inc. filed an 8-K report detailing a Regulation FD Disclosure and Other Events. The filing includes financial statements and exhibits, but specific financial figures or new material events are not detailed in the provided text snippet. The company's principal executive offices are located at 700 Quince Orchard Road, Gaithersburg, Maryland.

Why It Matters

This filing indicates Novavax is providing updates to the SEC, which could include material information relevant to investors.

Risk Assessment

Risk Level: low — The provided text is a standard SEC filing header and does not contain specific material events or financial data that would indicate a high-risk situation.

Key Players & Entities

  • NOVAVAX, INC. (company) — Registrant
  • 700 Quince Orchard Road Gaithersburg , Maryland 20878 (location) — Principal Executive Offices
  • June 6, 2024 (date) — Date of Report

FAQ

What specific events are disclosed in this 8-K filing?

The filing indicates it pertains to Regulation FD Disclosure and Other Events, along with Financial Statements and Exhibits, but the specific details of these events are not provided in the excerpt.

What is Novavax, Inc.'s principal executive office address?

Novavax, Inc.'s principal executive offices are located at 700 Quince Orchard Road, Gaithersburg, Maryland 20878.

When was this 8-K report filed?

This 8-K report was filed on June 6, 2024.

What is Novavax's state of incorporation?

Novavax, Inc. is incorporated in Delaware.

What is the SIC code for Novavax, Inc.?

The Standard Industrial Classification (SIC) code for Novavax, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).

Filing Stats: 1,620 words · 6 min read · ~5 pages · Grade level 14.8 · Accepted 2024-06-06 07:00:20

Key Financial Figures

  • $0.01 — registered Common Stock, Par Value $0.01 per share NVAX The Nasdaq Global Se

Filing Documents

01. Other Items

Item 8.01. Other Items. The U.S. Food and Drug Administration notified the Company that it completed its filing review of the final portion of the Company's Biologics License Application ("BLA") for its COVID-19 Vaccine and has set a Prescription Drug User Fee Act (PDUFA) review goal date in April 2025 for the BLA. As a result, the Company is planning for the commercial sales of its COVID-19 Vaccine in the United States during the 2024-2025 season to be under its existing Emergency Use Authorization. Cautionary Note Regarding Forward-Looking Statements . This Current Report on Form 8-K and the Investor Presentation attached as Exhibit 99.1 include forward-looking statements including information relating to the future of the Company, statements related to potential royalties and milestones, its near-term priorities including delivering an updated single-dose vial COVID-19 vaccine for the start of the 2024-2025 vaccination season, initiating a pivotal Phase 3 trial for CIC in the second half of 2024, a possible combination vaccine launch in 2026, reducing rate of spend, managing cash flow and evolving its scale and structure, the amount and impact of the Company's previously announced global restructuring and cost reduction plan and new cost reduction plan, its operating plans, objectives and prospects, its future financial or business performance, conditions or strategies, its partnerships, including with respect to the launch of R21/Matrix-M Malaria vaccine, the ongoing development of its updated COVID-19 vaccine and COVID-19-Influenza Combination (CIC) investigational vaccine candidate, the scope, timing and outcome of future and pending regulatory filings and actions, the availability of its updated COVID-19 vaccine, the fall 2024 and future global COVID-19 market opportunities, and the timing of delivery and distribution of its vaccine. Generally, forward-looking statements can be identified through the use of words or phrases such as "believe," "may," "coul

Forward-looking statements are neither historical facts nor assurances

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs and expectations about the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Forward-looking statements involve estimates, assumptions, risks, and uncertainties that could cause actual results or outcomes to differ materially from those expressed or implied in any forward-looking statements, and, therefore, you should not place considerable reliance on any such forward-looking statements. Such risks and uncertainties include, without limitation, our and Sanofi's ability to successfully implement its partnership, including the ability to transition key processes and effect technology transfers, Novavax's and Sanofi's ability to successfully develop or commercialize any vaccines or vaccine candidates, our ability to successfully and timely manufacture, distribute, or market our updated COVID-19 vaccine including as a single dose vial or pre-filled product presentation for the 2024-2025 vaccination season, our plans to sell our COVID-19 vaccine for the 2024-2025 vaccination season under Emergency Use Authorization; challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification, assay validation and stability testing, necessary to satisfy applicable regulatory authorities; challenges or delays in conducting clinical trials; challenges or delays in obtaining regulatory authorization for our product candidates, including our updated COVID-19 vaccine in time for the 2024-2025 vaccination season in the U.S. and in foreign jurisdictions to meet APA commitments or for future COVID-19 variant strain changes , our COVID-19-Influenza combination vaccine candidate and our stand-alone influenza vaccine candidate ; manufacturing, distribution

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Novavax, Inc. Date: June 6, 2024 By: /s/ Mark Casey Name: Mark Casey Title: Executive Vice President, Chief Legal Officer and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.